Join us on 12-15-2022 for a live seminar about RNA SEQ
Our Discovery Services augment your own expertise or give you capacity when you need it. Our team of leading scientists runs bespoke drug discovery campaigns for our partners and is continually innovating to validate and utilize cutting edge technology in our discovery offerings.
Our most popular service offering, DeepImmune, combines Alloy’s proprietary in vivo, in vitro, and in silico technologies into one process for time- and cost-efficient discovery of human monoclonal and bispecific therapeutic antibodies. DeepImmune integrates all our platforms and methods to generate, retrieve, and assess natural immune responses enabling successful discovery of potent antibody drug candidates ready for development.
GENERATE
Combining Alloy’s rapidly expanding family of ATX-Gx™ humanized mouse strains with advanced immunization protocols to generate highly diverse immune responses even to the most challenging antigens.
DeepImmune combines Alloy’s rapidly expanding family of ATX-Gx™ humanized mouse strains with advanced immunization strategies, custom antibody libraries, and machine learning-generated insights and libraries to generate highly diverse immune responses to even the most challenging antigens.
Our DeepImmune process captures the full diversity of antigen specific B-cells through sophisticated single cell technologies, immune phage libraries, and proprietary hybridoma protocols—all supported by next generation sequencing and deep learning-assisted immune repertoire analysis.
Capturing full diversity of antigen specific B-cells through sophisticated single-cell technologies, immune phage libraries, and proprietary hybridoma protocols all supported by the next generation sequencing and Deep Learning-assisted immune repertoire analysis.
The DeepImmune process uses an iterative design, test, learn feedback model to characterize and assess the biophysical and functional properties of your antibody hits to identify your top lead candidates by merging antibody-specific analytical methods with functional characterization and developability assessment, enabled by machine learning engine for sequence data mining.
Robust hit characterization and lead identification workflow merging antibody-specific analytical methods with functional characterization and developability assessment supported by machine learning engine for sequence data mining.
Rachel Rennard, CTO, Antibodies and Head of Antibody Discovery Services Boston
We work together to discover the best therapeutic antibody candidate, every time.
Keyway TCR Discovery is the first and only fully integrated discovery service for soluble therapeutics against peptide-MHCs. Keyway has developed a proprietary platform that you can access through our Discovery Services for TCRm today and engineered TCRs by the end of 2023. Keyway TCRm encompasses proprietary antibody-like bispecific formats for simultaneous effector cell engagement and target engagement.
Our fully integrated offering combines our ATX-Gx mouse platform with our in vivo, in vitro, and in silico capabilities for TCRm antibody identification and bioanalytical characterization, engineering, specificity screening, and functional characterization.
Our highly engineered display system integrates T cell sorting and sequencing; in vitro display including our proprietary mammalian cell display; machine-learning-guided affinity and specificity engineering; TCR libraries for naive discovery; and HLA display for specificity screening, target discovery and validation, and library on library panning.
We accelerate partner programs by providing early insights into functional activity of therapeutic candidates generated from Alloy discovery programs across all modalities. Generally, we offer these services in line with DeepImmune for human antibody discovery and Keyway for therapeutic TCR discovery, but we can offer advice and services on a case-by-case basis for our license partners and ecosystem collaborators.
Our first platform, the ATX-Gx™, is the world’s fastest growing transgenic mouse platform for human monoclonal antibody discovery. Partners may ship mice to their labs, work with an ATX-Gx certified service provide, or engage with our flagship antibody discovery service, DeepImmune.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Learn more about licensing our platforms for use your lab or starting a campaign with DeepImmune.
We’ve built a robust unique Deep Learning and sequencing engine that characterizes immune repertoire data, rapidly identifies novel binders, and optimizes candidates by scanning the breadth of sequence variants.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
We are also active in genetic medicines, peptides, cell therapy, and drug delivery technology through new Venture Studio companies, discovery services, and internal innovation projects.
Learn more about our work in these areas.
We are innovating across 6 modalities in our R&D facilities around the world and through our collaborations. Today partners can license platforms and access services in Antibodies and TCRs. We have active R&D activities and collaborations with amazing researchers around the world in all of our modalities. Our broad suite enables discovery of innovative new therapeutics with minimal restrictions.
Stay in the loop as we expand with additional platforms and services across modalities.
82VS, our affiliated Venture Studio, partners with target-rich biotech companies and scientific entrepreneurs to create new companies that can advance promising drug pipelines.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
San Francisco, CA
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.